2nd Quarter - Report

ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC) for ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

* On April 30, ADLM joined with other healthcare groups in writing to House and Senate appropriators in support of providing $340 million to fund the Centers for Disease Control and Prevention Public Health Data Modernization program. *On May 14, ADLM joined with other healthcare groups in writing Senate appropriators in support of providing $100 mllion for the Public Health Workforce Loan Repayment Program and $50 million to launch a Bio-Preparedness Workforce Pilot Program in the FY25 budget. * On May 31, ADLM joined with other healthcare groups in submitting testimony to the Select Subcommittee on the Coronavirus Pandemic, Committee on Oversight and Accountability, in support of strengthening the nation's public health workforce.

LobbyistCovered position, as disclosed
VINCENT STINE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

* On April 2, ADLM provided feedback to Senator Bill Cassidy (R-LA) on the need diagnostic testing reform.v * On April 8, ADLM provided survey results to Senator Bill Cassidy (R-LA) illustrating problems with the Food and Drug Administration's October 3, 2023 proposed rule to regulate laboratory developed tests. * On June 24, 2024 ADLM provided additional survey results to Senate HELP and House Energy & Commerce Committee leaders identifying concerns with the May 6, 2024 FDA final rule on LDTs. * ADLM met with House and Senate legislative staff in support of the Saving Access to Laboratory Services Act, H.R.1835 & S.1000, and conducted a grassroots campaign in support of the bill. *ADLM conducted a grassroots campaign in support of congressional action to revoke the May 6, 2024 FDA rule on LDTs.

LobbyistCovered position, as disclosed
VINCENT STINE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1835 (118th), S. 1000 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.